Literature DB >> 22184124

Cys-27 variant of human δ-opioid receptor modulates maturation and cell surface delivery of Phe-27 variant via heteromerization.

Tarja T Leskelä1, Jarkko J Lackman, Miia M Vierimaa, Hiroyuki Kobayashi, Michel Bouvier, Ulla E Petäjä-Repo.   

Abstract

The important role of G protein-coupled receptor homo/heteromerization in receptor folding, maturation, trafficking, and cell surface expression has become increasingly evident. Here we investigated whether the human δ-opioid receptor (hδOR) Cys-27 variant that shows inherent compromised maturation has an effect on the behavior of the more common Phe-27 variant in the early secretory pathway. We demonstrate that hδOR-Cys-27 acts in a dominant negative manner and impairs cell surface delivery of the co-expressed hδOR-Phe-27 and impairs conversion of precursors to the mature form. This was demonstrated by metabolic labeling, Western blotting, flow cytometry, and confocal microscopy in HEK293 and human SH-SY5Y neuroblastoma cells using differentially epitope-tagged variants. The hδOR-Phe-27 precursors that were redirected to the endoplasmic reticulum-associated degradation were, however, rescued by a pharmacological chaperone, the opioid antagonist naltrexone. Co-immunoprecipitation of metabolically labeled variants revealed that both endoplasmic reticulum-localized precursors and mature receptors exist as homo/heteromers. The existence of homo/heteromers was confirmed in living cells by bioluminescence resonance energy transfer measurements, showing that the variants have a similar propensity to form homo/heteromers. By forming both homomers and heteromers, the hδOR-Cys-27 variant may thus regulate the levels of receptors at the cell surface, possibly leading to altered responsiveness to opioid ligands in individuals carrying the Cys-27 variant.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22184124      PMCID: PMC3281609          DOI: 10.1074/jbc.M111.305656

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  Monitoring receptor oligomerization using time-resolved fluorescence resonance energy transfer and bioluminescence resonance energy transfer. The human delta -opioid receptor displays constitutive oligomerization at the cell surface, which is not regulated by receptor occupancy.

Authors:  M McVey; D Ramsay; E Kellett; S Rees; S Wilson; A J Pope; G Milligan
Journal:  J Biol Chem       Date:  2001-01-22       Impact factor: 5.157

2.  Newly synthesized human delta opioid receptors retained in the endoplasmic reticulum are retrotranslocated to the cytosol, deglycosylated, ubiquitinated, and degraded by the proteasome.

Authors:  U E Petaja-Repo; M Hogue; A Laperriere; S Bhalla; P Walker; M Bouvier
Journal:  J Biol Chem       Date:  2000-10-27       Impact factor: 5.157

3.  Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation.

Authors:  Ulla E Petäjä-Repo; Mireille Hogue; Suparna Bhalla; André Laperrière; Jean-Pierre Morello; Michel Bouvier
Journal:  EMBO J       Date:  2002-04-02       Impact factor: 11.598

4.  Variant detection at the delta opioid receptor (OPRD1) locus and population genetics of a novel variant affecting protein sequence.

Authors:  J Gelernter; H R Kranzler
Journal:  Hum Genet       Date:  2000-07       Impact factor: 4.132

5.  Inefficient maturation of the rat luteinizing hormone receptor. A putative way to regulate receptor numbers at the cell surface.

Authors:  E Maritta Pietilä; Jussi T Tuusa; Pirjo M Apaja; Jyrki T Aatsinki; Anna E Hakalahti; Hannu J Rajaniemi; Ulla E Petäjä-Repo
Journal:  J Biol Chem       Date:  2005-05-18       Impact factor: 5.157

6.  Quantitative assessment of beta 1- and beta 2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer.

Authors:  Jean-François Mercier; Ali Salahpour; Stéphane Angers; Andreas Breit; Michel Bouvier
Journal:  J Biol Chem       Date:  2002-09-19       Impact factor: 5.157

7.  A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications.

Authors:  Takeharu Nagai; Keiji Ibata; Eun Sun Park; Mie Kubota; Katsuhiko Mikoshiba; Atsushi Miyawaki
Journal:  Nat Biotechnol       Date:  2002-01       Impact factor: 54.908

8.  Naturally occurring deletional mutation in the C-terminal cytoplasmic tail of CCR5 affects surface trafficking of CCR5.

Authors:  T Shioda; E E Nakayama; Y Tanaka; X Xin; H Liu; A Kawana-Tachikawa; A Kato; Y Sakai; Y Nagai; A Iwamoto
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

9.  Homo- and hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences.

Authors:  Douglas Ramsay; Elaine Kellett; Mary McVey; Stephen Rees; Graeme Milligan
Journal:  Biochem J       Date:  2002-07-15       Impact factor: 3.857

10.  Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis.

Authors:  Sonia Terrillon; Thierry Durroux; Bernard Mouillac; Andreas Breit; Mohammed A Ayoub; Magali Taulan; Ralf Jockers; Claude Barberis; Michel Bouvier
Journal:  Mol Endocrinol       Date:  2002-12-23
View more
  9 in total

Review 1.  Psychiatric drugs bind to classical targets within early exocytotic pathways: therapeutic effects.

Authors:  Henry A Lester; Julie M Miwa; Rahul Srinivasan
Journal:  Biol Psychiatry       Date:  2012-07-06       Impact factor: 13.382

Review 2.  The prevalence, maintenance, and relevance of G protein-coupled receptor oligomerization.

Authors:  Graeme Milligan
Journal:  Mol Pharmacol       Date:  2013-04-30       Impact factor: 4.436

Review 3.  Chaperoning G protein-coupled receptors: from cell biology to therapeutics.

Authors:  Ya-Xiong Tao; P Michael Conn
Journal:  Endocr Rev       Date:  2014-03-24       Impact factor: 19.871

Review 4.  Molecular Pharmacology of δ-Opioid Receptors.

Authors:  Louis Gendron; Catherine M Cahill; Mark von Zastrow; Peter W Schiller; Graciela Pineyro
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

5.  N-Glycan-dependent and -independent quality control of human δ opioid receptor N-terminal variants.

Authors:  Jarkko J Lackman; Piia M H Markkanen; Mireille Hogue; Michel Bouvier; Ulla E Petäjä-Repo
Journal:  J Biol Chem       Date:  2014-05-05       Impact factor: 5.157

Review 6.  Pharmacological chaperoning: a primer on mechanism and pharmacology.

Authors:  Nancy J Leidenheimer; Katelyn G Ryder
Journal:  Pharmacol Res       Date:  2014-02-14       Impact factor: 7.658

Review 7.  Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens.

Authors:  P Michael Conn; David C Smithson; Peter S Hodder; M David Stewart; Richard R Behringer; Emery Smith; Alfredo Ulloa-Aguirre; Jo Ann Janovick
Journal:  Pharmacol Res       Date:  2013-12-25       Impact factor: 7.658

8.  Candidate gene analyses for acute pain and morphine analgesia after pediatric day surgery: African American versus European Caucasian ancestry and dose prediction limits.

Authors:  Jin Li; Zhi Wei; Jie Zhang; Hakon Hakonarson; Scott D Cook-Sather
Journal:  Pharmacogenomics J       Date:  2019-02-14       Impact factor: 3.550

Review 9.  Inside job: ligand-receptor pharmacology beneath the plasma membrane.

Authors:  Joseph J Babcock; Min Li
Journal:  Acta Pharmacol Sin       Date:  2013-05-20       Impact factor: 6.150

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.